|Bid||220.00 x 1400|
|Ask||220.92 x 900|
|Day's Range||220.02 - 225.49|
|52 Week Range||215.78 - 344.00|
|Beta (3Y Monthly)||1.45|
|PE Ratio (TTM)||8.20|
|Earnings Date||Oct 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||253.65|
Health care stocks, one of the worst performing sectors, could be poised to outperform even as election turmoil heats up next year. Now, better-than-expected earnings from both UnitedHealth Group Inc. (UNH) and Johnson & Johnson (JNJ) have highlighted health care companies' strong earnings amid a dim overall corporate profit outlook. Health care companies have strong underlying businesses, a factor becoming more attractive in the market as investors shift away from “riskier” assets and more expensive, loss-making companies. And from a valuation perspective, the weakness in the health care space has led many investors to buy health care stocks, which are selling at discounted prices.
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
Biogen and Regeneron Pharmaceuticals are most likely among large-cap biotech companies to top Wall Street's third-quarter sales and earnings expectations, an analyst said Friday.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
MISSISSAUGA, ON , Oct. 3, 2019 /CNW/ - Biogen Canada is pleased to announce results from the NURTURE study, which demonstrated that infants who initiated treatment with SPINRAZA™ (nusinersen injection) prior to the onset of clinical symptoms of spinal muscular atrophy (SMA) attained positive results compared to the natural history of the disease. NURTURE is the first study investigating a treatment targeting the underlying cause of spinal muscular atrophy (SMA) in infants treated pre-symptomatically.
Biogen Inc. (BIIB) today announced that the journal Neuromuscular Disorders has published data from NURTURE, the first study investigating a treatment targeting the underlying cause of spinal muscular atrophy (SMA) in infants treated pre-symptomatically. Data from the NURTURE study demonstrated that infants who initiated treatment with SPINRAZA prior to the onset of clinical symptoms attained unparalleled results compared to the natural history of the disease.
Biogen stock lost nearly 30% of its value in mid-March when the biotech company scrapped two studies of a late-stage Alzheimer’s treatment. Is now time to invest in Biogen stock?
In a statement, Biogen's head of research and development, Michael Ehlers, said he believes it is “the right time to pass the baton.”
Biogen Inc. said Tuesday it has named Dr. Alfred Sandrock as executive vice president of research and development, a role he will take on alongside his current role of chief medical officer. Sandrock will replace Dr Michael Ehlers, who has decided to leave the company effective Oct. 11. The company said it has also named Dr Alphonse Galdes as EVP of pharmaceuticals operations and technology. Sandrock has been chief medical officer of Biogen since 2012 and has served on the executive committee since 2015. Shares were down 0.3% premarket and have fallen 27.6% in 2019, while the S&P 500 has gained 18.7%.
Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President,.
While the S&P 500 is up nearly 19% heading into the final quarter of the year, biotech stocks are badly lagging the market, punishing the performance of many ETFs and other funds holding shares of companies such as Biogen (BIIB), Regeneron Pharmaceuticals Inc. (REGN), BioMarin Pharmaceutical Inc. (BMRN), Gilead Sciences Inc. (GILD), Vertex Pharmaceuticals Inc. (VRTX), and Alexion Pharmaceuticals Inc. (ALXN). The increasingly bearish sentiment is reflected in six consecutive weeks of outflows from biotech funds, amounting to about $2.1 billion, and marking the longest stretch of continuous outflows in nearly two years, as outlined by Barron’s. Weakness in the biotech sector has caused a long list of ETFs to fall sharply from their highs in the last few months, including the giant iShares Nasdaq Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and Invesco Dynamic Biotechnology & Genome ETF (PBE), just to name a few.
The historical evidence (for long-term-oriented investors) overwhelmingly supports the argument that the secret to success in stocks is not to get scared out of them -- but staying the course isn't easy, notes value investing expert John Buckingham, money manager and editor of The Prudent Speculator.
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Biogen Inc. (BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the of the European Medicines Agency (EMA), recommended an update to marketing authorizations of approved interferon beta treatments, including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), to remove pregnancy contraindications and, where clinically needed, to allow use during pregnancy and breastfeeding in women with relapsing multiple sclerosis (MS). “Women are diagnosed with MS at least two to three times more frequently than men,1 and the disease may strike during their child-bearing years.2 Choosing a treatment plan that allows women to continue or start their MS therapy while pregnant or breastfeeding is a step forward for those living with this chronic, debilitating disease and their partners,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen.